



Transparency notification BlackRock, Inc.

Brussels (Belgium), 8 June 2017 – 20:00 (CEST) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 2 June 2017, from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, U.S.A.).

BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has increased and has crossed the 3% threshold of voting rights on 1 June 2017.

On 1 June 2017, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 836 096 UCB shares with voting rights (versus 5 822 269 shares in its previous notification dated 2 June 2017 referring to its shareholding on 31 May 2017), representing 3.00% of the total number of shares issued by the company (194 505 658) (versus 2.99% in the notification dated 2 June 2017 referring to its shareholding on 31 May 2017).

2. Content of the notification

The transparency notification dated 2 June 2017 includes the following information:

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
BlackRock, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Advisors, LLC	100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada
BlackRock Asset Management Deutschland AG	Max-Joseph-Straße 6, Munich, 80333, Germany
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong
BlackRock Financial Management, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.
BlackRock International Limited	Exchange Place One, 1 Sempole Street, Edinburgh, EH3 8BL, U.K.
BlackRock Investment Management (Australia) Limited	Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan

- **Date on which the threshold is crossed:** 1 June 2017.
- **Threshold crossed (in %):** 3%.
- **Denominator:** 194 505 658.
- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
BlackRock, Inc.	0	0		0,00%	
BlackRock (Netherlands) B.V.	18.125	18.125		0,01%	
BlackRock (Singapore) Limited	7.531	6.980		0,00%	
BlackRock Advisors (UK) Limited	693.728	683.470		0,35%	
BlackRock Advisors, LLC	76.325	76.325		0,04%	
BlackRock Asset Management Canada Limited	59.233	59.233		0,03%	
BlackRock Asset Management Deutschland AG	230.489	230.489		0,12%	
BlackRock Asset Management North Asia Limited	760	760		0,00%	
BlackRock Financial Management, Inc.	61.045	60.509		0,03%	
BlackRock Fund Advisors	2.074.448	2.075.606		1,07%	
BlackRock Institutional Trust Company, National Association	1.905.944	1.906.593		0,98%	
BlackRock International Limited	6.461	6.461		0,00%	
BlackRock Investment Management (Australia) Limited	43.395	43.395		0,02%	
BlackRock Investment Management (UK) Limited	216.811	231.376		0,12%	
BlackRock Investment Management, LLC	264.480	264.477		0,14%	
BlackRock Japan Co., Ltd.	163.494	172.297		0,09%	
Subtotal	5.822.269	5.836.096		3,00%	
TOTAL		5.836.096	0	3,00%	0,00%

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
BlackRock Advisors (UK) Limited	Securities Lent			236.789	0,12%	physical
BlackRock Fund Advisors	Securities Lent			14.553	0,01%	physical
BlackRock Institutional Trust Company, National Association	Securities Lent			529	0,00%	physical
BlackRock Japan Co., Ltd.	Securities Lent			5.438	0,00%	physical
BlackRock Institutional Trust Company, National Association	Contract for Difference			11.945	0,01%	cash
BlackRock International Limited	Contract for Difference			6.423	0,00%	cash
BlackRock Investment Management (UK) Limited	Contract for Difference			104.045	0,05%	cash
TOTAL				379.722	0,20%	

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	6.215.818	3,20%

- **Chain of controlled undertakings through which the holding is effectively held:**

Please see the full chain of control in the PDF which is attached to the notification.

- **Additional information:**

The disclosure obligation arose due to voting rights attached to shares for BlackRock, Inc. going above 3%.

3. Further information

This press release and the detailed transparency notification is available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of €4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news